BREAKING: Early-stage venture firm Breakout Ventures has just announced the closing of its third fund, totaling $114 million. Based in San Francisco, this fund will target groundbreaking technologies in biology, chemistry, and artificial intelligence, responding to a surge of interest in science and deep tech.
The announcement comes on the heels of a significant triumph for Breakout’s portfolio company, Surf Bio, which was recently acquired by Halozyme Therapeutics for up to $400 million. This acquisition underscores the momentum in the biotech sector and the potential for substantial returns on investments in scientific innovation.
Returning investors, including Cortes Capital and S-Cubed Capital, have backed the new fund, alongside newcomers like JIMCO and Korea Omega Investment Corporation. The influx of capital highlights a growing confidence in the commercialization of scientific breakthroughs.
In a notable shift, Breakout Ventures has promoted Nima Ronaghi to partner, reflecting his vital role in guiding investments and supporting portfolio companies. Managing Partner Lindy Fishburne remarked, “As AI is unleashed on the scale of data in biology and chemistry, we are experiencing incredible speed, momentum, and efficiency that are fundamentally changing cost curves and return profiles.”
Breakout Ventures has a history of investing early in startups transforming scientific research into market-ready products. Their previous fund, launched in 2021, has already yielded significant successes. Alongside Surf Bio, the portfolio includes innovative companies like Cytovale, which has created an AI-enabled diagnostic test for sepsis, and Twelve, focused on producing aviation fuel from captured carbon.
The firm is also backing emerging companies, including Reach Industries, which specializes in computer vision systems for regulated industries. Additionally, two stealth-mode startups are set to revolutionize the commercialization of scientific discoveries and enhance computational tools for small-molecule discovery.
With the launch of Fund III, Breakout Ventures is poised to continue its legacy of supporting scientific founders as they navigate the complexities of bringing groundbreaking technologies to market. Investors and industry watchers alike are eager to see how these developments will unfold, marking a pivotal moment in the intersection of technology and biology.
This urgent news reflects the rapidly changing landscape of investment in science-driven startups, making it critical for stakeholders to stay informed and engaged as these trends develop.
